These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31701524)

  • 21. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
    Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
    Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
    Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
    Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
    Claudiani S; Marktel S; Piemontese S; Assanelli A; Lupo-Stanghellini MT; Carrabba M; Guggiari E; Giglio F; De Freitas T; Marcatti M; Bernardi M; Corti C; Peccatori J; Lunghi F; Ciceri F
    Hematol Oncol; 2016 Sep; 34(3):154-60. PubMed ID: 25469485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
    Harris AC; Boelens JJ; Ahn KW; Fei M; Abraham A; Artz A; Dvorak C; Frangoul H; Freytes C; Gale RP; Hong S; Lazarus HM; Loren A; Mineishi S; Nishihori T; O'Brien T; Williams K; Pasquini MC; Levine JE
    Blood Adv; 2018 Jun; 2(11):1198-1206. PubMed ID: 29844205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
    Bernardo ME; Piras E; Vacca A; Giorgiani G; Zecca M; Bertaina A; Pagliara D; Contoli B; Pinto RM; Caocci G; Mastronuzzi A; La Nasa G; Locatelli F
    Blood; 2012 Jul; 120(2):473-6. PubMed ID: 22645178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
    Shea TC; Walko C; Chung Y; Ivanova A; Sheets J; Rao K; Gabriel D; Comeau T; Wood W; Coghill J; Armistead P; Sarantopoulos S; Serody J
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2129-2135. PubMed ID: 26210442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
    Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Ayala E; Perez L; Fernandez H; Fancher K; Tate C; Shaw LM; Milone MC; Gardiner JA; Miller S; Anasetti C
    Bone Marrow Transplant; 2011 Nov; 46(11):1418-25. PubMed ID: 21132026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
    Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.
    Shimoni A; Bielorai B; Toren A; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Exp Hematol; 2003 May; 31(5):428-34. PubMed ID: 12763142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.
    Langenhorst JB; van Kesteren C; van Maarseveen EM; Dorlo TPC; Nierkens S; Lindemans CA; de Witte MA; van Rhenen A; Raijmakers R; Bierings M; Kuball J; Huitema ADR; Boelens JJ
    Blood Adv; 2019 Jul; 3(14):2179-2187. PubMed ID: 31324638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
    Casper J; Holowiecki J; Trenschel R; Wandt H; Schaefer-Eckart K; Ruutu T; Volin L; Einsele H; Stuhler G; Uharek L; Blau I; Bornhaeuser M; Zander AR; Larsson K; Markiewicz M; Giebel S; Kruzel T; Mylius HA; Baumgart J; Pichlmeier U; Freund M; Beelen DW
    Bone Marrow Transplant; 2012 Sep; 47(9):1171-7. PubMed ID: 22158386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
    van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
    Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.